The role of hematopoietic stem cell transplant in follicular lymphoma

Edward A. Faber, Julie Marie Vose

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Substantial progress has been made in the clinical management of patients with follicular lymphoma over the past 2 decades. However, the role of autologous and allogeneic stem cell transplantation in these patients remains controversial. Myeloablative chemotherapy or radioimmunotherapy supported by autologous hematopoietic cell transplantation has been shown to lead to a longer progression-free survival and, in some studies, improved survival over standard therapy. However, in the era of rituximab-based therapies used as part of induction or salvage, these historical trials may not be representative. Allogeneic stem cell transplantation offers the advantages of a tumor-free graft and some immunologic graft-versus-lymphoma effects. However, fully myeloablative transplants have high morbidity and mortality rates. Dose-reduced conditioning regimens followed by allogeneic hematopoietic cell transplantation have substantially reduced treatment-related mortality and perhaps will produce better outcomes long-term. This article outlines some historical information regarding stem cell transplantation for follicular lymphoma and discusses recent modifications that may improve outcomes, such as adding radio-immunotherapy to autologous stem cell transplantation or using alternative dose-reduced regimens that could benefit patients with reduced toxicities.

Original languageEnglish (US)
Pages (from-to)337-344
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume8
Issue number3
StatePublished - Mar 1 2010

Fingerprint

Follicular Lymphoma
Stem Cell Transplantation
Hematopoietic Stem Cells
Transplants
Cell Transplantation
Radioimmunotherapy
Mortality
Radio
Immunotherapy
Disease-Free Survival
Lymphoma
Therapeutics
Morbidity
Drug Therapy
Survival
Neoplasms

Keywords

  • Allogeneic hematopoietic cell transplantation
  • Autologous hematopoietic cell transplantation
  • Follicular lymphoma
  • Monoclonal antibodies
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

The role of hematopoietic stem cell transplant in follicular lymphoma. / Faber, Edward A.; Vose, Julie Marie.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 8, No. 3, 01.03.2010, p. 337-344.

Research output: Contribution to journalArticle

@article{7d98100709404445ab36cd581147fa9a,
title = "The role of hematopoietic stem cell transplant in follicular lymphoma",
abstract = "Substantial progress has been made in the clinical management of patients with follicular lymphoma over the past 2 decades. However, the role of autologous and allogeneic stem cell transplantation in these patients remains controversial. Myeloablative chemotherapy or radioimmunotherapy supported by autologous hematopoietic cell transplantation has been shown to lead to a longer progression-free survival and, in some studies, improved survival over standard therapy. However, in the era of rituximab-based therapies used as part of induction or salvage, these historical trials may not be representative. Allogeneic stem cell transplantation offers the advantages of a tumor-free graft and some immunologic graft-versus-lymphoma effects. However, fully myeloablative transplants have high morbidity and mortality rates. Dose-reduced conditioning regimens followed by allogeneic hematopoietic cell transplantation have substantially reduced treatment-related mortality and perhaps will produce better outcomes long-term. This article outlines some historical information regarding stem cell transplantation for follicular lymphoma and discusses recent modifications that may improve outcomes, such as adding radio-immunotherapy to autologous stem cell transplantation or using alternative dose-reduced regimens that could benefit patients with reduced toxicities.",
keywords = "Allogeneic hematopoietic cell transplantation, Autologous hematopoietic cell transplantation, Follicular lymphoma, Monoclonal antibodies, Radioimmunotherapy",
author = "Faber, {Edward A.} and Vose, {Julie Marie}",
year = "2010",
month = "3",
day = "1",
language = "English (US)",
volume = "8",
pages = "337--344",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",

}

TY - JOUR

T1 - The role of hematopoietic stem cell transplant in follicular lymphoma

AU - Faber, Edward A.

AU - Vose, Julie Marie

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Substantial progress has been made in the clinical management of patients with follicular lymphoma over the past 2 decades. However, the role of autologous and allogeneic stem cell transplantation in these patients remains controversial. Myeloablative chemotherapy or radioimmunotherapy supported by autologous hematopoietic cell transplantation has been shown to lead to a longer progression-free survival and, in some studies, improved survival over standard therapy. However, in the era of rituximab-based therapies used as part of induction or salvage, these historical trials may not be representative. Allogeneic stem cell transplantation offers the advantages of a tumor-free graft and some immunologic graft-versus-lymphoma effects. However, fully myeloablative transplants have high morbidity and mortality rates. Dose-reduced conditioning regimens followed by allogeneic hematopoietic cell transplantation have substantially reduced treatment-related mortality and perhaps will produce better outcomes long-term. This article outlines some historical information regarding stem cell transplantation for follicular lymphoma and discusses recent modifications that may improve outcomes, such as adding radio-immunotherapy to autologous stem cell transplantation or using alternative dose-reduced regimens that could benefit patients with reduced toxicities.

AB - Substantial progress has been made in the clinical management of patients with follicular lymphoma over the past 2 decades. However, the role of autologous and allogeneic stem cell transplantation in these patients remains controversial. Myeloablative chemotherapy or radioimmunotherapy supported by autologous hematopoietic cell transplantation has been shown to lead to a longer progression-free survival and, in some studies, improved survival over standard therapy. However, in the era of rituximab-based therapies used as part of induction or salvage, these historical trials may not be representative. Allogeneic stem cell transplantation offers the advantages of a tumor-free graft and some immunologic graft-versus-lymphoma effects. However, fully myeloablative transplants have high morbidity and mortality rates. Dose-reduced conditioning regimens followed by allogeneic hematopoietic cell transplantation have substantially reduced treatment-related mortality and perhaps will produce better outcomes long-term. This article outlines some historical information regarding stem cell transplantation for follicular lymphoma and discusses recent modifications that may improve outcomes, such as adding radio-immunotherapy to autologous stem cell transplantation or using alternative dose-reduced regimens that could benefit patients with reduced toxicities.

KW - Allogeneic hematopoietic cell transplantation

KW - Autologous hematopoietic cell transplantation

KW - Follicular lymphoma

KW - Monoclonal antibodies

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=77949854479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949854479&partnerID=8YFLogxK

M3 - Article

C2 - 20202463

AN - SCOPUS:77949854479

VL - 8

SP - 337

EP - 344

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 3

ER -